Teva Pharmaceuticals

Published Online: Tuesday, July 23, 2013
Follow Pharmacy_Times:

Teva Pharmaceutical Industries Ltd is a fully integrated global pharmaceutical company, focusing its business in 3 primary areas: generic, specialty, and OTC medicines. Approximately 51% of the company’s revenue is generated in the US.

Teva Pharmaceuticals is the leading generic drug company in the US. In 2012, Teva accounted for 16.2% of US generic prescriptions, with 1 of every 6* generic prescriptions being filled with a Teva product. The company’s strategy for its generic business is to continue to extract maximum value from Paragraph IV patent challenge opportunities; establish a leadership position in high-value generics by pursuing first-to-market opportunities and by developing complex generic products; and to enhance the value of its portfolio by concentrating on high-margin, low-competition markets.

*IMS Health NPA data as of 12/2012.

Teva’s Levalbuterol Inhalation Solution, USP, AN rated to Xopenex® (levalbuterol HCl) Inhalation Solution.

Teva recently introduced generic versions of Maxalt® (rizatriptan benzoate) Tablets.

Teva has 144 ANDAs pending FDA approval as of April 18, 2013, and introduced 23 generic products in 2012. The company markets the broadest product line in the industry, with nearly 400 generic products and 1300 dosage strengths and package sizes, covering all major therapeutic categories. Teva also produces approximately 300 APIs in many therapeutic areas.

Teva’s strategy also includes a disciplined and focused approach to enhancing its specialty-branded portfolio, concentrating on the therapeutic areas of CNS, respiratory, oncology, and women’s health. Teva’s specialty portfolio includes COPAXONE®, AZILECT®, NUVIGIL®, ProAir®, and TREANDA®. As part of this strategy, Teva is focusing on new therapeutic entities (“NTEs”), which are known molecules that are formulated, delivered, or used in a novel way to address specific patient needs.

Teva Pharmaceuticals
1090 Horsham Road
P.O. Box 1090 North Wales, PA 19454-1090
Phone: 800-545-8800

 For more information, visit

Related Articles
Today Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa) introduced H.R. 5815, The Generic Drug Pricing Fairness Act, which creates greater transparency in how pharmacy benefit managers reimburse pharmacies for generic prescription drugs under Medicare Part D, and the Federal Employees Health Benefits Program. The National Community Pharmacists Association endorsed the bill, which goes further than legislation the same two Congressmen introduced earlier year that has the same remedies, but only applied to Medicare Part D.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.
Generics saved $239 billion in 2013 (a 14% increase in savings from 2012) and more than $1.46 trillion over the recent decade. Further, the Express Scripts 2013 Drug Trend Report issued in 2014 shows that since 2008, the price of brand drugs has almost doubled, but the price of generic drugs has been cut roughly in half.
Latest Issues